Subtype
Uveal Melanoma
CI-CAN-00001637UVMExplore in graph →
59 active trials1 approved drugs17 evidence items
- NCIt
- C7712
- OncoTree
- UM
- DOID
- 6039
- UMLS CUI
- C0220633
- MeSH
- D000098943
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001637UVMExplore in graph →
Clinical trials
232 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (34)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05524935 | Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma | active not recruiting | Phase 2 | 12 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05607095 | A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma | recruiting | Phase 1 | 40 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 15, 2026 |
| clinicaltrials |
| NCT07804186 | Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma | recruiting | Phase 3 | 450 | IDEAYA BiosciencesINDUSTRY | 2 | Sep 15, 2026 | clinicaltrials |
| NCT02678572 | Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma(FOCUS) | completed | Phase 3 | 102 | Delcath Systems Inc.INDUSTRY | 9 | Sep 10, 2026 | clinicaltrials |
| NCT05903937 | Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases(HAITILS-PHP) | not yet recruiting | Phase 1 | 6 | Vastra Gotaland RegionOTHER_GOV | 0 | Sep 9, 2026 | clinicaltrials |
| NCT06070012 | Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma | recruiting | Phase 2 | 44 | Diwakar DavarOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07183852 | Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic Melanoma(GoTIL-01) | not yet recruiting | Phase 1 | 18 | Vastra Gotaland RegionOTHER_GOV | 0 | Sep 9, 2026 | clinicaltrials |
| NCT07803562 | Low Dose Dexamethasone for the Prevention of Cytokine Release Syndrome Associated With Tebentafusp(LODEXA) | not yet recruiting | Phase 2 | 34 | University of California, San DiegoOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07076550 | A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma | terminated | Phase 1 | 5 | Alpha-9 Oncology USA Inc.INDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT03025256 | Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease | active not recruiting | Phase 1 | 75 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07338968 | A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma(CoMpass) | enrolling by invitation | — | 100 | Aura BiosciencesINDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07636785 | A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors(SPKTAHC) | recruiting | Phase 1 / Phase 2 | 111 | VM Discovery, Inc.INDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05308901 | Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma | terminated | Phase 2 | 6 | Providence Health & ServicesOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT04588662 | A Prospective Natural History Study in Uveal Melanoma | active not recruiting | — | 122 | Columbia UniversityOTHER | 5 | Aug 11, 2026 | clinicaltrials |
| NCT04855435 | Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours | recruiting | Phase 1 | 106 | MonTa Biosciences ApSINDUSTRY | 2 | Aug 10, 2026 | clinicaltrials |
| NCT01979523 | Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma | active not recruiting | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 3 | Aug 6, 2026 | clinicaltrials |
| NCT07747935 | Study of Neoadjuvant RBP-01 In Patients With Primary Uveal Melanoma(Uveal Melanoma) | not yet recruiting | Phase 1 / Phase 2 | 30 | ReBio PharmaINDUSTRY | 0 | Aug 5, 2026 | clinicaltrials |
| NCT06007690 | A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma(CoMpass) | active not recruiting | Phase 3 | 108 | Aura BiosciencesINDUSTRY | 14 | Jul 31, 2026 | clinicaltrials |
| NCT01587352 | Vorinostat in Treating Patients With Metastatic Melanoma of the Eye | active not recruiting | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jul 29, 2026 | clinicaltrials |
| NCT05282901 | Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME)(PLUME) | completed | Phase 2 | 51 | Institut CurieOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT05415072 | A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas | active not recruiting | Phase 1 / Phase 2 | 66 | Novartis PharmaceuticalsINDUSTRY | 7 | Jul 28, 2026 | clinicaltrials |
| NCT03417739 | A Phase II Study of BVD-523 in Metastatic Uveal Melanoma | terminated | Phase 2 | 13 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT06626516 | Tebentafusp-tebn With LDT in Metastatic UM | recruiting | Phase 1 / Phase 2 | 109 | Thomas Jefferson UniversityOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT04328844 | A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers | active not recruiting | Phase 1 | 210 | iOncturaINDUSTRY | 2 | Jul 8, 2026 | clinicaltrials |
| NCT03472586 | Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver | completed | Phase 2 | 14 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT03635632 | C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) | active not recruiting | Phase 1 | 94 | Baylor College of MedicineOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07501117 | Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma | recruiting | Phase 1 | 15 | Inge Marie SvaneOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06246149 | Adjuvant Tebentafusp in High Risk Ocular Melanoma(ATOM) | recruiting | Phase 3 | 290 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Jun 30, 2026 | clinicaltrials |
| NCT01989572 | Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery | completed | Phase 3 | 815 | National Cancer Institute (NCI)NIH | 1 | Jun 24, 2026 | clinicaltrials |
| NCT06932757 | Adjuvant Quisinostat in High-Risk Uveal Melanoma | recruiting | Phase 2 | 63 | University of MiamiOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT05075993 | Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors | active not recruiting | Phase 1 | 352 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06414590 | Neoadjuvant Tebentafusp for Uveal Melanoma | recruiting | Phase 2 | 19 | Thomas Jefferson UniversityOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT03947385 | Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions | recruiting | Phase 1 / Phase 2 | 336 | IDEAYA BiosciencesINDUSTRY | 3 | Jun 8, 2026 | clinicaltrials |
| NCT07627698 | Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma(DUET-MEL) | recruiting | Phase 1 / Phase 2 | 36 | Beijing BiotechINDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT03467516 | Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma | active not recruiting | Phase 2 | 34 | Udai KammulaOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT03941379 | A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma | active not recruiting | — | 63 | Aura BiosciencesINDUSTRY | 1 | May 22, 2026 | clinicaltrials |
| NCT04728633 | Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases | active not recruiting | Phase 2 | 28 | Thomas Jefferson UniversityOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07015190 | Neoadjuvant Darovasertib in Primary Uveal Melanoma | recruiting | Phase 3 | 520 | IDEAYA BiosciencesINDUSTRY | 21 | May 6, 2026 | clinicaltrials |
| NCT07203391 | Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis(TRIUMPH) | recruiting | Phase 1 | 8 | St Vincent's Hospital, SydneyOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT05377957 | Prospective Registration Of Patient Data and Quality of Life in Eye Melanoma Patients(PROQEM) | active not recruiting | — | 500 | Leiden University Medical CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05170334 | Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma | active not recruiting | Phase 2 | 7 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT05496686 | Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma | active not recruiting | Phase 1 | 16 | Modulation Therapeutics, Inc.INDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT05628883 | Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma | completed | Phase 1 | 17 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT06581406 | A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma | recruiting | Phase 2 / Phase 3 | 280 | Replimune, Inc.INDUSTRY | 3 | Apr 2, 2026 | clinicaltrials |
| NCT07276386 | Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma | recruiting | Phase 2 | 18 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT06075589 | Psychoeducation for Uveal Melanoma | active not recruiting | N/A | 108 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT06550674 | Identification of New Candidate Genes for Hereditary Predisposition to Uveal Melanoma(IGCMU) | recruiting | N/A | 50 | Centre Jean PerrinOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT03070392 | Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma | completed | Phase 2 | 378 | Immunocore LtdINDUSTRY | 14 | Mar 17, 2026 | clinicaltrials |
| NCT04119024 | Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors | recruiting | Phase 1 | 18 | Anusha KalbasiOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT02068586 | Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma | active not recruiting | Phase 2 | 210 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Mar 16, 2026 | clinicaltrials |
Data updated 14 days agoSource updated Sep 15, 2026source: clinicaltrials